Pharmasset is developing oral drugs to treat hepatitis C, which is now largely treated with injections.
(istockphoto.com)
MARKET MOVERS
Pharmasset to be acquired for $11b
Pharmasset is developing oral drugs to treat hepatitis C, which is now largely treated with injections.
(istockphoto.com)
November 27, 2011
Text size
–
+
Gilead Sciences Inc. paid about $11 billion for experimental hepatitis C drug maker Pharmasset Inc. to win a “competitive’’ acquisition process and replace an unsuccessful therapy under development, said Chief Operating Officer John Milligan.
For more from BostonGlobe.com, sign up or log in below
To continue, please sign up or log in to BostonGlobe.com
Access the full articles and quality reporting of The Boston Globe at BostonGlobe.com
Sign up
Unlimited Access to BostonGlobe.com for 4 weeks for only 99¢.
Are you a Boston Globe home delivery subscriber?
Get FREE access as part of your print subscription.
BostonGlobe.com subscriber
Click to continue reading this article or to log in to BostonGlobe.com.
